News Update
Advancing Gene Therapies And Curative Health Care Through Value-Based Payment Reform
Read more from Spark Therapeutics CEO Jeff Marrazzo, bluebird bio CEO Nick Leschly is CEO, Duke-Margolis deputy director for policy Gregory Daniel and director Mark McClellan on the Health Affairs blog.
The companies are members of and provide support to a value-based payment consortium convened by Duke-Margolis.